| Reshaping human antibodies for therapy L Riechmann, M Clark, H Waldmann, G Winter Nature 332 (6162), 323-327, 1988 | 3576 | 1988 |
| Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes B Keymeulen, E Vandemeulebroucke, AG Ziegler, C Mathieu, L Kaufman, ... New England journal of medicine 352 (25), 2598-2608, 2005 | 1298 | 2005 |
| Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. M Brüggemann, GT Williams, CI Bindon, MR Clark, MR Walker, R Jefferis, ... The Journal of experimental medicine 166 (5), 1351-1361, 1987 | 1086 | 1987 |
| Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo SP Cobbold, A Jayasuriya, A Nash, TD Prospero, H Waldmann Nature 312 (5994), 548-551, 1984 | 1077 | 1984 |
| " Infectious" transplantation tolerance S Qin, SP Cobbold, H Pope, J Elliott, D Kioussis, J Davies, H Waldmann Science 259 (5097), 974-977, 1993 | 1030 | 1993 |
| CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. A Davies, DL Simmons, G Hale, RA Harrison, H Tighe, PJ Lachmann, ... The Journal of experimental medicine 170 (3), 637-654, 1989 | 731 | 1989 |
| Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H G Hale, MR Clark, R Marcus, G Winter, MJS Dyer, JM Phillips, ... The Lancet 332 (8625), 1394-1399, 1988 | 729 | 1988 |
| Identification of regulatory T cells in tolerated allografts L Graca, SP Cobbold, H Waldmann The Journal of experimental medicine 195 (12), 1641-1646, 2002 | 707 | 2002 |
| Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. S Meri, BP Morgan, A Davies, RH Daniels, MG Olavesen, H Waldmann, ... immunology 71 (1), 1, 1990 | 690 | 1990 |
| Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL) J Lundin, E Kimby, M Björkholm, PA Broliden, F Celsing, V Hjalmar, ... Blood, The Journal of the American Society of Hematology 100 (3), 768-773, 2002 | 685 | 2002 |
| Heterogeneity of natural Foxp3+ T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity N Komatsu, ME Mariotti-Ferrandiz, Y Wang, B Malissen, H Waldmann, ... Proceedings of the National Academy of Sciences 106 (6), 1903-1908, 2009 | 654 | 2009 |
| Plasticity of Foxp3+ T cells reflects promiscuous Foxp3 expression in conventional T cells but not reprogramming of regulatory T cells T Miyao, S Floess, R Setoguchi, H Luche, HJ Fehling, H Waldmann, ... Immunity 36 (2), 262-275, 2012 | 646 | 2012 |
| Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis AJ Coles, MG Wing, P Molyneux, A Paolillo, CM Davie, G Hale, D Miller, ... Annals of Neurology: Official Journal of the American Neurological …, 1999 | 614 | 1999 |
| In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation PD Kottaridis, DW Milligan, R Chopra, RK Chakraverty, S Chakrabarti, ... Blood, The Journal of the American Society of Hematology 96 (7), 2419-2425, 2000 | 603 | 2000 |
| The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy AJ Coles, A Cox, E Le Page, J Jones, SA Trip, J Deans, S Seaman, ... Journal of neurology 253, 98-108, 2006 | 599 | 2006 |
| The plasticity and stability of regulatory T cells S Sakaguchi, DAA Vignali, AY Rudensky, RE Niec, H Waldmann Nature Reviews Immunology 13 (6), 461-467, 2013 | 572 | 2013 |
| Limiting dilution analysis of cells in the immune system I Lefkovits, H Waldmann | 553 | 1979 |
| Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis AJ Coles, M Wing, S Smith, F Coraddu, S Greer, C Taylor, A Weetman, ... The Lancet 354 (9191), 1691-1695, 1999 | 533 | 1999 |
| Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients R Calne, P Friend, S Moffatt, A Bradley, G Hale, J Firth, J Bradley, K Smith, ... The Lancet 351 (9117), 1701-1702, 1998 | 526 | 1998 |
| Induction of foxP3+ regulatory T cells in the periphery of T cell receptor transgenic mice tolerized to transplants SP Cobbold, R Castejon, E Adams, D Zelenika, L Graca, S Humm, ... The Journal of Immunology 172 (10), 6003-6010, 2004 | 522 | 2004 |
